• 1.華西醫(yī)科大學(xué)附屬第一醫(yī)院普外科(成都610041);;
  • 2.華西醫(yī)科大學(xué)附屬第一醫(yī)院腫瘤研究所;;
  • 3.華西醫(yī)科大學(xué)附屬第一醫(yī)院生物治療中心;;
  • 4.華西醫(yī)科大學(xué)法醫(yī)學(xué)院物證室;

目的  研究反義硫代磷酸寡核苷酸(AS-ODN)抑制人肝癌細(xì)胞耐藥株(SMMC-7721／ADM)MRP基因表達(dá)的作用。
方法  用人工合成互補(bǔ)于MRP基因mRNA特定片斷的反義硫代磷酸寡核苷酸，以脂質(zhì)體Lipofectamine為載體轉(zhuǎn)染SMMC-7721／ADM細(xì)胞株，用RT-PCR測(cè)定mRNA表達(dá)，流式細(xì)胞技術(shù)測(cè)定細(xì)胞膜MRP1蛋白P190表達(dá)及MTT法檢測(cè)細(xì)胞對(duì)柔紅霉素(DNR)和阿霉素(ADM)的敏感性。
結(jié)果  AS-ODN能抑制MRP mRNA和其蛋白P190表達(dá)，提高細(xì)胞對(duì)DNR和ADM的敏感性。
結(jié)論  ①AS-ODN能降低MRP基因表達(dá)； ②MRP介導(dǎo)的多藥耐藥(MDR)是SMMC-7721／ADM耐藥的重要機(jī)理之一。

引用本文： 楊家印,羅華友,林琦遠(yuǎn),嚴(yán)律南,林萍,雷松,黃代新,趙永恒. 反義寡核苷酸降低細(xì)胞株SMMC-7721／ADM之MRP基因表達(dá)的研究. 中國(guó)普外基礎(chǔ)與臨床雜志, 2001, 8(3): 141-144. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of transporter gene in a multidrugresistant human lung cancer cell line 〔J〕. Science, 1992； 258(5088)∶1650.
2. Stewart AJ, Canitrot Y, Banacchini E, et al. Reduction of expression of the multidrug resistance protein(MRP) in human tumor cells by antisense phosphorothioate oligonucleotides 〔J〕. Biochem Pharm, 1996； 51(4)∶461.
3. 劉炳仁，楊純正，欒鳳君等.用逆轉(zhuǎn)錄多聚酶鏈反應(yīng)檢測(cè)白血病患者多藥耐藥基因的表達(dá) 〔J〕.中華血液學(xué)雜志，1995； 16(2)∶65.
4. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeioid lekaemia 〔J〕. Br J Cancer, 1989； 60(2)∶206.
5. Nakamura H, Oda Y, Iwai S, et al. How does Rnase H recognize a DNARNA hybrid 〔J〕? Pro Natl Acad Sci USA, 1991； 88(24)∶11535.
6. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids 〔J〕. Biochem Biophys Acta, 1990； 1049(2)∶99.
7. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense 〔J〕? Br J Cancer, 1993； 67(5)∶869.
8. Richert ND, Aldwin L, Nitesci D, et al. Stability and covalent modification of Pglycoprotein in multidrug resistant KB cells 〔J〕. Biochemistry, 1988； 27(20)∶7607.
  1. 1. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of transporter gene in a multidrugresistant human lung cancer cell line 〔J〕. Science, 1992； 258(5088)∶1650.
  2. 2. Stewart AJ, Canitrot Y, Banacchini E, et al. Reduction of expression of the multidrug resistance protein(MRP) in human tumor cells by antisense phosphorothioate oligonucleotides 〔J〕. Biochem Pharm, 1996； 51(4)∶461.
  3. 3. 劉炳仁，楊純正，欒鳳君等.用逆轉(zhuǎn)錄多聚酶鏈反應(yīng)檢測(cè)白血病患者多藥耐藥基因的表達(dá) 〔J〕.中華血液學(xué)雜志，1995； 16(2)∶65.
  4. 4. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeioid lekaemia 〔J〕. Br J Cancer, 1989； 60(2)∶206.
  5. 5. Nakamura H, Oda Y, Iwai S, et al. How does Rnase H recognize a DNARNA hybrid 〔J〕? Pro Natl Acad Sci USA, 1991； 88(24)∶11535.
  6. 6. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids 〔J〕. Biochem Biophys Acta, 1990； 1049(2)∶99.
  7. 7. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense 〔J〕? Br J Cancer, 1993； 67(5)∶869.
  8. 8. Richert ND, Aldwin L, Nitesci D, et al. Stability and covalent modification of Pglycoprotein in multidrug resistant KB cells 〔J〕. Biochemistry, 1988； 27(20)∶7607.